ABVC BioPharma Provides 2023 Pipeline Update
February 28, 2023 08:30 ET
|
ABVC BioPharma, Inc.
FREMONT, CA, Feb. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
American BriVision Initiates Phase II Part I Clinical Trial for ABV-1505 in Adult Attention-Deficit Hyperactivity Disorder (ADHD)
December 05, 2019 08:31 ET
|
American BriVision Holding Corporation
PDC-1421, the active ingredient of ABV-1505, is being expanded into adult ADHD trials following encouraging Phase II trial results in major depressive disorder (MDD) Phase II Part I trial of...
American BriVision Announces Issuance of a Full Clinical Study Report (CSR) for ABV-1504 for Major Depressive Disorder Phase II Study
November 14, 2019 13:22 ET
|
American BriVision Holding Corporation
PDC-1421 high-dose data meets primary endpoint on MADRS scale in ITT clinical trial population PDC-1421 low-dose and PDC-1421 high-dose each proved safe, were well-tolerated, and had no...